MRA of the Supraaortic Vasculature: Comparison of Gadobutrol and Gadoterate Meglumine at 1.5 T
Abstract
Background
Gadobutrol (GB) and gadoterate meglumine (GM) are contrast agents used for contrast-enhanced magnetic resonance angiography (CEMRA). Supraaortic vasculature (SAV) CEMRAs are used to evaluate stroke risk and neurologic symptoms. There is a need to compare the SAV CEMRA image quality obtained with GB and GM.
Purpose
To intra-individually compare MRA images obtained with equimolar GB and GM at 1.5 T in the SAV.
Study Type
Prospective, crossover.
Population
Twenty-eight subjects (54 ± 13 years; 17 female).
Field Strength/Sequence
1.5 T; three-dimensional (3D) gradient recalled echo.
Assessment
Quantitative image quality was measured by normalized signal intensity (SIn) [SIn = SI blood/SD blood] and contrast ratio (CR) [CR = SI blood/SI muscle], determined by an observer (JWC) with 1 year of vascular imaging experience. Three radiologists (AS, PA, and MU) with (5, 5, and 6 years of) vascular imaging experience evaluated image quality by Likert-scale ratings (of image impression, wall conspicuity, and artifact absence).
Statistical Tests
SIn and CR were compared with paired t-tests or Wilcoxon signed-rank tests and Bland–Altman plots. Qualitative ratings were compared with Wilcoxon signed-rank test.
Results
No significant difference in SIn was found between GB and GM. CRs with GB were significantly higher than GM at the right common carotid (6.9 ± 2.5 vs. 4.8 ± 1), left internal carotid (7.3 ± 2 vs. 4.4 ± 1.2), right internal carotid (7.7 ± 2.2 vs. 5 ± 1.1), and left vertebral (6.6 ± 2.2 vs. 4.5 ± 1.1) arteries. Bland–Altman plots showed relatively greater differences between GB and GM at higher CRs and SIns. GM showed significantly higher artifact than GB (3.56 ± 0.52 vs. 3.36 ± 0.46) and significantly lower overall image quality (10.73 ± 1.45 vs. 11.26 ± 1.58) at the left vertebral artery.
Data Conclusion
At 1.5 T and equimolar demonstration, GB (0.1 mL/kg, i.e., 0.1 mmol/kg) showed higher CRs in the SAV compared to GM (0.2 mL/kg, i.e., 0.1 mmol/kg) at most vessels. Subjective image quality was not significantly different between the two agents for most vessels.
Level of Evidence
2
Technical Efficacy
Stage 2
Conflict of Interest
JCC is the principal investigator for this Guerbet funded study. He declares that he has previously participated in advisory boards for Bayer, Guerbet, and Bracco. He participates in speaking roles sponsored by Bayer. He has received institutional research support sponsored by Bayer, Guerbet, and Siemens. MM has received research support from Siemens. He has received research grants from Circle Cardiovascular imaging and Cryolife incorporated. BDA has performed consulting for Circle Cardiovascular Imaging. He has been funded by the American Heart Association. RA has performed consulting for Circle Cardiovascular Imaging.
Open Research
Data Availability Statement
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
